Advertisement
Research Article Free access | 10.1172/JCI59410
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Froese, A. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Breher, S. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Waldeyer, C. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Schindler, R. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Nikolaev, V. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Rinné, S. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Wischmeyer, E. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Schlueter, J. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Becher, J. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Simrick, S. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Vauti, F. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Kuhtz, J. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Meister, P. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Kreissl, S. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Torlopp, A. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Liebig, S. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Laakmann, S. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Müller, T. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Neumann, J. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Stieber, J. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Ludwig, A. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Maier, S. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Decher, N. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Arnold, H. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Kirchhof, P. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Fabritz, L. in: JCI | PubMed | Google Scholar
1Cell and Developmental Biology, University of Würzburg, Würzburg, Germany. 2Department of Cardiology and Angiology, University Hospital Münster and IZKF Münster, Münster, Germany. 3Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. 4Institute for Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, Marburg, Germany. 5Institute of Physiology II, University of Würzburg, Würzburg, Germany. 6Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 7Heart Science Centre, Imperial College London, Harefield, United Kingdom. 8Cell and Molecular Biology, University of Braunschweig, Braunschweig, Germany. 9Molecular Plant Physiology and Biophysics, University of Würzburg, Würzburg, Germany. 10Institute of Pharmacology and Toxicology, University of Halle-Wittenberg, Halle, Germany. 11Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Find articles by Brand, T. in: JCI | PubMed | Google Scholar
Authorship note: Alexander Froese and Stephanie S. Breher are co–first authors. Larissa Fabritz and Thomas Brand are co–senior authors.
Published February 22, 2012 - More info
The electrical impulses that dictate the rhythm of the heartbeat in normal situations and during exercise or stress are initiated by a small number of sinus node pacemaker cells. Senescence and dysfunction of the sinus node affects many people later in life, causing physiologically inappropriate heart rates, but the underlying mechanisms are not well understood. In this issue of the JCI, Froese and colleagues show that deficiency in either Popeye domain containing 1 (Popdc1) or Popdc2 leads to sinus node dysfunction under stressed conditions in aged mice. The mechanism reported to underlie the effects of Popdc1/2 deficiency in mice may cause the stress-induced sinus node dysfunction found in many aged individuals and may point to new strategies for therapeutic intervention.
Bastiaan J. Boukens, Vincent M. Christoffels
Cardiac pacemaker cells create rhythmic pulses that control heart rate; pacemaker dysfunction is a prevalent disorder in the elderly, but little is known about the underlying molecular causes. Popeye domain containing (Popdc) genes encode membrane proteins with high expression levels in cardiac myocytes and specifically in the cardiac pacemaking and conduction system. Here, we report the phenotypic analysis of mice deficient in Popdc1 or Popdc2. ECG analysis revealed severe sinus node dysfunction when freely roaming mutant animals were subjected to physical or mental stress. In both mutants, bradyarrhythmia developed in an age-dependent manner. Furthermore, we found that the conserved Popeye domain functioned as a high-affinity cAMP-binding site. Popdc proteins interacted with the potassium channel TREK-1, which led to increased cell surface expression and enhanced current density, both of which were negatively modulated by cAMP. These data indicate that Popdc proteins have an important regulatory function in heart rate dynamics that is mediated, at least in part, through cAMP binding. Mice with mutant Popdc1 and Popdc2 alleles are therefore useful models for the dissection of the mechanisms causing pacemaker dysfunction and could aid in the development of strategies for therapeutic intervention.
Cardiac myocytes are able to conduct electrical activity. However, only specialized pacemaker myocytes, which are located in the sinus node, are normally able to initiate cardiac action potentials (1). Nodal myocytes are small, have few myofibrils, and are electrically poorly coupled (2). At the gene expression level, the sinus node and working myocardium display mostly quantitative rather than qualitative differences (3, 4). HCN4, a pore-forming subunit that is responsible for the pacemaker current If, is commonly used to distinguish nodal from chamber myocardium (2). Pacemaking is accomplished by a network of ion channels (M-clock) that act together to generate the pacemaker potential and also involves intracellular Ca2+ oscillations (Ca2+-clock) (5–7). Activation of the β-adrenergic receptor leads to the positive chronotropic effect of catecholamines on cardiac automaticity. Enhanced pacemaker activity is believed to involve direct binding of cAMP to HCN channels, but also depends on PKA-dependent phosphorylation of several ion channels that drive the pacemaker potential in sinus node cells (5).
The Popeye domain containing (Popdc) genes encode a family of membrane proteins that are abundantly expressed in heart and skeletal muscle (8–11). In vertebrates, 3 Popdc genes are present: Popdc1 (previously known as Pop1; ref. 9; and also referred to as Bves; ref. 8), Popdc2 (previously known as Pop2), and Popdc3 (previously known as Pop3) (8, 9, 12–15). Popdc proteins contain 3 transmembrane helices and the evolutionary conserved cytoplasmic Popeye domain (10, 11). It has been hypothesized that Popdc1 is involved in regulating cell migration, since a loss of Popdc1 results in early embryonic lethality as a result of defective gastrulation in Xenopus and aberrant germ band extension in Drosophila (16, 17). In mice, Popdc1 is required for skeletal muscle regeneration (18). Of the 3 Popdc genes, Popdc2 shows the highest and most selective expression in myocardium; however, no heart-specific function has been defined for Popdc genes (8–11).
Here, we show that both Popdc1 and Popdc2 genes were abundantly expressed in the cardiac pacemaking and conduction system. Mice deficient for either gene developed severe stress-induced cardiac bradycardia in an age-dependent manner. Popdc proteins bound cAMP with high affinity and therefore functioned as mediators in β-adrenergic signal transduction. We also demonstrated that Popdc proteins bound to the 2-pore domain potassium channel TREK-1 and recruited it to the plasma membrane. This protein interaction was negatively modulated by cAMP. Our present findings led us to conclude that members of the Popdc gene family represent a novel class of cAMP-binding proteins that apparently have a regulatory role in the cardiac pacemaking and conduction system.
To investigate the functional relevance of Popdc2, we generated a null mutant mouse by replacing the coding region of exon I by a LacZ reporter gene (Supplemental Figure 1, A–D; supplemental material available online with this article; doi: 10.1172/JCI59410DS1). The Popdc2 null mutant was viable and displayed no obvious pathological phenotype other than reduced weight gain. A cohort of 30 mutant and control littermates was analyzed in the primary systemic screen of the German Mouse Clinic (19), and phenotyping screening data were deposited in the GMC Phenomap database ( http://www.mouseclinic.de/phenomap/reports/Popdc2.pdf). Although Popdc2 is highly expressed in the heart, cardiac morphology and function seemed unaltered in the mutant (Supplemental Figure 1, E–H). Although marker gene expression was increased, no morphological evidence for cardiac hypertrophy was obtained (Supplemental Figure 1, I and J). Popdc1 and Popdc3 expression was not elevated in Popdc2 null mutants (Supplemental Figure 1J).
Popdc2 null mutant mice develop stress-induced bradycardia. Popdc2 is expressed in cardiac myocytes (20) and showed high levels of expression in the sinus and atrioventricular (AV) nodes (Figure 1, A–D). ECG recordings in freely roaming WT and mutant mice at sedentary state revealed no differences in mean heart rate and rate variability (Supplemental Figure 2A and Supplemental Table 1). In contrast, 5.5- and 8-month-old Popdc2–/– animals undergoing physical activity (i.e., swimming exercise) exhibited a mean heart rate that was significantly lower than in WT mice, but was unaltered in 3-month-old mutants (Figure 1, E and F). Similar age-dependent chronotropic incompetence was found when Popdc2–/– mice were subjected to mental stress or after direct β-adrenergic stimulation (Supplemental Figure 2B and Supplemental Table 1). Analysis of individual ECG tracings revealed severe sinus node dysfunction (SND) with long pauses and intercurrent periods of normal sinus rhythm (Figure 1G and Supplemental Figure 2C). A sinoatrial block appeared unlikely, since the variation in cycle length at the beginning of a bradycardic period was not a multiple of the preceding cycle length (Supplemental Figure 2D). The number of stress-induced pauses in Popdc2–/– mice increased in an age-dependent manner: young adult animals (3 months of age) did not show stress-induced pauses, whereas pauses were common at 8 months of age (Figure 1H). PQ intervals did not differ between genotypes (Figure 1I). Anesthetized mice were subjected to invasive electrophysiological testing of AV node function. The Wenckebach point was not altered in Popdc2 null mutants (WT, 77.50 ± 5.3, n = 10; Popdc2–/–, 83.73 ± 3.2, n = 15 per group; P = NS). The AV node in null mutants was able to elicit an escape rhythm during sinus node pauses. We observed narrow and broad-QRS complex escape rhythms in Popdc2 null mutants (Supplemental Figure 3, D and E), which suggests that the AV node was not functionally impaired. The mutant heart phenotype was not likely due to a defect in autonomic innervation or tone, since isolated, beating, autonomically deprived hearts of Popdc2–/– mutants also showed more sinus pauses than did WT littermates during β-adrenergic stimulation (Figure 1J). The drop in mean heart rates after carbachol administration was similar in mutant and WT mice (Supplemental Figure 2E and Supplemental Table 1), indicative of normal responsiveness to parasympathetic stimulation. From these data, we concluded that the Popdc2–/– mouse has an intrinsic deficiency to adapt heart rate to physiological stress, which develops in older mice and is mediated at least in part by a blunted heart rate response to catecholamines.
Popdc2–/– mice develop a stress-induced bradycardia. (A) Consecutive sections of a Popdc2+/– mouse heart were stained for β-galactosidase (LacZ) and acetylcholine esterase (AChE). (B) A section through the vena cava region was LacZ stained for 10 or 80 minutes. (C) Whole-mount LacZ staining and (D) in situ hybridization for Popdc2. Arrowheads and arrows in A, C, and D denote sinus and AV nodes, respectively. RA, right atrium; SAN, sinus node. Scale bars: 1 mm (A); 200 μm (B); 500 μm (C and D). (E) Heart rate distribution (y axis) of 8-month-old Popdc2–/– and WT mice before (green), during (blue), and after (red) swim stress, depicted on a beat per beat basis (x axis). (F) Age-dependent mean heart rates of WT and Popdc2–/– mice during and after swimming. *P < 0.05 between genotypes (n = 5–12). (G) ECG recordings of 8-month-old Popdc2–/– and WT mice during swim stress test. Asterisks indicate P waves. Horizontal bar: 100 ms. (H) Number of pauses in WT and Popdc2–/– mice during a 30-minute period after swim stress (log scale on y axis) as a function of age (x axis). *P < 0.05 between genotypes (n = 5–12). (I) PQ intervals measured at 600, 450, and 150 bpm (n = 5 per genotype and heart rate). ne, nonexistent in WT. (J) Number of isolated hearts with sinus pauses after β-adrenergic stimulation. *P < 0.05 between genotypes; #P < 0.05, baseline vs. catecholamine.
Stress-induced bradycardia is also observed in the Popdc1 null mutant. The presence of a rate-dependent phenotype in Popdc2 null mutants prompted us to ask whether Popdc1 deficiency could cause a similar phenotype, although no cardiac pathology has been reported previously (18). Popdc1, which is expressed in the heart (18), showed high prevalence in the cardiac pacemaking and conduction system (Figure 2, A–E). Sedentary Popdc1 null mutant and WT littermate controls showed no difference in mean heart rate and heart rate variability (data not shown). In contrast, after 5 minutes of swimming exercise, the mean heart rate of 8-month-old Popdc1–/– mice was lower than that of WT mice (Popdc1–/–, 593 ± 39 bpm; WT, 701 ± 16 bpm), and severe repetitive drops of the heart rate were observed during and after swim stress (Figure 2F). This abnormality became severe with increasing age in Popdc1–/– mice, with significantly more pauses at 5.5 and 8 months of age (Figure 2G). Similar to the Popdc2 null mutant, heart rate increase in response to mental stress or catecholamines was blunted in Popdc1–/– mice (Supplemental Figure 4A) and in isolated, beating Popdc1–/– hearts (Supplemental Figure 4B).
Functional deficits in Popdc1–/– mice. (A–C) Whole-mount LacZ staining of (A) sinus node, (B and C) His bundle (His), and (B) left and (C) right bundle branches (BB). Ao, aorta; SVC, superior vena cava. (D) Consecutive sections through the His bundle were stained for LacZ, acetylcholine esterase, and Popdc1. (E) Immunofluorescent detection of Popdc1 and HCN4 and merged images in the sinus node. Shown are composites of multiple images. endo, endocardial; epi, epicardial. Scale bars: 100 μm. (F) Heart rate (y axis) of Popdc1–/– and WT mice before (green), during (blue), and after (red) swim stress, depicted on a beat per beat basis (x axis). (G) Age-dependent mean heart rates of WT and Popdc1–/– mice during and directly after swimming. Shown are mean heart rates (y axes) as a function of age (x axes). *P < 0.05 between genotypes (n = 5–12). (H) ECG recordings of Popdc1–/– and WT mice during swim stress test. Asterisks indicate P waves. Horizontal bar: 100 ms. (I) Number of pauses in WT and Popdc1–/– mice during a 30-minute period after swim stress (log scale on y axis) as a function of age (x axis). *P < 0.05 between genotypes (n = 5–12). (J) PQ intervals measured at 600, 450, and 150 bpm (n = 5 per genotype and heart rate).
Individual ECG recordings of Popdc1–/– and WT mice during swim tests revealed severe SND with long pauses interrupting periods of normal sinus rhythm (Figure 2H). The increase of stress-induced pauses in Popdc1–/– mice at 8 months of age was striking and amounted to an average of 581 ± 300 pauses during a 30-minute interval after physical exercise compared with 4 ± 2 pauses in WT mice (Figure 2I). The PQ intervals were comparable between the genotypes (Figure 2J). Escape rhythms showed both narrow and broad QRS complexes (Supplemental Figure 3, A–C), consistent with a normal AV nodal automaticity in Popdc1–/– mice.
Abnormalities in sinus node structure in Popdc1 and Popdc2 null mutants. In order to search for a structural basis of the bradycardia phenotype in Popdc null mutants, sinus node preparations of 8-month-old Popdc2–/– animals were whole-mount stained using an antibody directed against HCN4 (2). The sinus node in WT animals revealed a complex network of nodal myocytes having thin cellular extensions (Figure 3, A, C, and E). In contrast, pacemaker cells in Popdc2 null mutants displayed a reduced number of these extensions, and the node had a more compact structure (Figure 3, B, D, and F). 3D reconstructions of consecutive Hcn4-stained sections indicated a loss of pacemaker tissue from the inferior part of the sinus node (Figures 3, G and H). Individual sections stained with Trichrome or HCN4 antibody also revealed tissue loss in the inferior sinus node and a compact structure of the superior sinus node in Popdc2 null mutants (Figure 3, I–P, and Supplemental Figure 5, E–H). We wondered whether the compact superior sinus node was the result of a phenotypic conversion of pacemaker myocytes into working myocardium; however, Cx43, a marker for chamber myocardium, was not ectopically expressed in Popdc2–/– mutants (Supplemental Figure 5, A–D). Sinus node preparations of 3-month-old Popdc2–/– mutants were indistinguishable from WT preparations (data not shown), which suggests that these histological alterations are only present at an age when the mutant displays pacemaker dysfunction. The loss of sinus node tissue may be responsible for the observed phenotype, since the primary pacemaker is known to shift from the center of the sinus node under resting conditions to the inferior part after adrenergic stimulation (21). Therefore, loss of tissue in this part of the sinus node may impair pacemaker activity, especially after adrenergic stimulation. However, it is equally likely that atrophy of the inferior sinus node may be the result of its dysfunction. Interestingly, very similar alterations of sinus node structure were observed in Popdc1 null animals (Supplemental Figure 6, A–F).
Structural alterations of the sinus node in Popdc2–/– mice. (A–D) Whole-mount immunohistochemistry of HCN4 expression in the sinus node. Boxed regions in A and B are enlarged in C and D, respectively. Arrowheads in C and D denote the network of filopodia-like extensions of nodal myocytes that were structurally abnormal in Popdc2–/– mice. (E and F) Whole-mount immunofluorescence staining of HCN4 in the sinus node illustrating an overall reduction of pacemaking cells in Popdc2–/– mice. (G and H) 3D reconstruction of the sinus node based on HCN4 expression. Arrowheads in E–H indicate reduction of HCN4 immunoreactivity in the inferior part of the sinus node in mutant mice. Bars at right denote approximate planes of sections shown in I–P. (I–L) Trichrome staining visualizing the histology and fibrotic tissue content in the superior (I and J) and inferior (K and L) region of the sinus node. (M–P) Immunohistochemistry for HCN4 expression in the superior (M and N) and inferior (O and P) part of the sinus node. Scale bars: 200 μm (A and B); 100 μm (C–P).
The Popeye domain functions as a high-affinity cAMP-binding domain. The Popeye domain represents a highly conserved structural feature of all Popdc proteins, yet its biochemical function is unknown. Secondary structure predictions of the Popeye domain revealed similarity to the cyclic nucleotide-binding domain of PKA (Figure 4A). However, the amino acid sequence of the putative phosphate-binding cassette (PBC) did not resemble that of other PBC sequences. We directly tested the ability of Popdc proteins to interact with cyclic nucleotides. Binding of native Popdc1 protein to cAMP was demonstrated through affinity precipitation (Figure 4B). Addition of free cAMP to bound Popdc1 protein resulted in a concentration-dependent elution from cAMP-agarose beads, demonstrating specificity of ligand binding. Binding of cAMP was established for all 3 members of the Popdc family (Figure 4C). Sequence alignment of Popeye domains from invertebrates and vertebrates revealed 25 invariant amino acids (data not shown), and 3D modeling allowed us to position most of these conserved residues within or near the putative PBC in the Popeye domain (Figure 4D). According to this model, 2 conserved sequence motifs (DSPE and FQVT) were predicted to be involved in cyclic nucleotide binding (Figure 4E). In order to test this prediction experimentally, we created point mutations in Popdc1 by exchanging the residues D200, P202, and E203 of the DSPE motif to alanine and residue V217 of the FQVT motif to phenylalanine. Popdc1D200A displayed cAMP-binding activity of less than 10% of WT protein, whereas the binding capacity of Popdc1P202A was unchanged (Figure 4F). Popdc1E203A and Popdc1V217A exhibited intermediate binding. A charged-to-alanine mutation of D184 in Popdc2 (which is analogous to D200 in Popdc1) also displayed a substantial reduction in cAMP binding (Figure 4G). To rule out that binding of Popdc proteins to cAMP-agarose is indirectly mediated by an interacting protein, we used a recombinant form of the Popeye domain in a radioimmunoassay. This protein was able to bind to cAMP with high affinity and specificity (cAMP IC50, 118.4 ± 7.1 nM; cGMP IC50, 5.27 ± 0.68 μM; Figure 4H).
The Popeye domain functions as a cyclic nucleotide-binding domain. (A) Secondary structure of human cAMP-dependent protein kinase type II-β regulatory subunit (PRKAR2B) and structural prediction of the Popeye domain of human POPDC1. Pink rods, α helices; yellow arrows, β strands; pink underlay, PBC. (B) Western blot detection of chick Popdc1 after affinity precipitation of cardiac tissue extracts incubated with cAMP-agarose. Bound Popdc1 protein was eluted with increasing amounts of cAMP. P, pellet; S, supernatant; T, total protein; C, control incubation using ethanolamine-agarose. (C) Western blot of Cos-7 cells transfected with Popdc1, Popdc2, and Popdc3 cDNAs. Shown are total protein and protein bound to cAMP-agarose or ethanolamine (EA) agarose. Brackets denote differentially glycosylated Popdc proteins; asterisks denote nonglycosylated form of Popdc proteins; arrowhead denotes unspecific immunoreactive protein. (D) 3D model of the Popeye domain of human POPDC1. Invariant amino acids are colored red. The cAMP moiety is shown as CPK model. (E) Enlargement of the predicted cAMP binding site. Predicted hydrogen bonds between cAMP and the DSPE and FQVT sequence motifs are shown as dashed lines. (F) Western blot of cAMP-agarose precipitations of Cos-7 cells transfected with cDNAs encoding Popdc1 and Popdc1D200A, Popdc1P202A, Popdc1E203A, or Popdc1V217F mutants. (G) Western blot of cAMP-agarose precipitations of Cos-7 cells transfected with cDNAs encoding Popdc2 or Popdc2D184A mutant. (H) Radioligand binding assay using [3H]-cAMP and recombinant C terminus of Popdc1. Binding was competed with increasing concentrations of free unlabeled cAMP and cGMP, respectively.
Popdc proteins enhance surface expression of the 2-pore domain potassium channel TREK-1. The membrane localization of Popdc1 and Popdc2 in cardiac myocytes (22), the high expression level in cardiac pacemaking tissue, and the heart rate–dependent phenotypes in null mutants suggest an electrical function of Popdc proteins. The If current is an essential part of the network of ion channels that act together to generate the pacemaker potential. We tested If current density and activation time in isolated sinus node myocytes from WT and Popdc2–/– mice. Cells of both genotypes were indistinguishable in current density under basal conditions and after superfusion with 8-Br-cAMP (Supplemental Figure 7A). Moreover, activation kinetics of sinus node cells from WT and Popdc2–/– mice were also similar (Supplemental Figure 7B). Therefore, pacemaker dysfunction in Popdc2–/– mice was not due to a primary dysfunction of If in sinus node cells. We also examined whether Popdc proteins might function as pore-forming units, but did not observe any change in currents in Xenopus oocytes after injection of Popdc cRNAs (data not shown). Cardiac myocytes are known to express several 2-pore domain potassium channels, including the stretch-activated K+ channel TREK-1 and the acid-sensitive K+ channel TASK-1 (23–25). We analyzed whether the gating properties of these channels might be affected by Popdc proteins. Coexpression of TASK-1 with either Popdc1 or Popdc2 did not alter conductivity (Figure 5A and data not shown). In contrast, coexpression of TREK-1 together with Popdc1, Popdc2, or Popdc3 resulted in a significant augmentation of the outward current measured at +30 mV (Figure 5, B and C). After treating oocytes with theophylline to chronically increase cAMP levels, the relative increase in TREK-1 current was abolished (Figure 5D). The increase in membrane current was likely the result of enhanced expression of TREK-1 at the cell surface, as revealed by a luminometric assay with HA epitope–tagged TREK-1 (Figure 5E). In order to obtain further evidence for a direct interaction between TREK-1 and members of the Popdc family, protein localization was studied in transfected Cos-7 cells. In cells transfected with Popdc1 alone, the protein was localized in the cytoplasm and at the plasma membrane (Figure 5F). In contrast, protein localization of TREK-1 alone was mainly present at the plasma membrane, where it induced filopodia formation, as reported previously (26). When both proteins were expressed simultaneously, they colocalized extensively at the plasma membrane (Figure 5G), which suggests that they form complexes. Interaction of both proteins was also demonstrated in GST pulldown experiments (Figure 5H). Popdc1 also showed substantial coexpression with TREK-1 in isolated adult ventricular cardiac myocytes and in cardiac tissues (Supplemental Figures 8 and 9).
Interaction of Popdc proteins with the 2-pore channel TREK-1. (A) Relative current amplitudes of TASK-1 alone or in the presence of Popdc2 were assayed in Xenopus oocytes 48–72 hours after injection (n = 28–31). Error bars in A and C–E are SEM. (B) Example of the measurement of TREK-1–mediated outward current after injection of TREK-1 cRNA alone (gray curve) or in the presence of Popdc1 (black curve) in Xenopus oocytes. (C) Relative current amplitudes of TREK-1 alone or in the presence of Popdc1, Popdc2, or Popdc3 (n = 14–22). *P < 0.05. (D) Relative TREK-1 current amplitudes in the presence or absence of Popdc2. The oocytes were incubated for 48 hours with or without theophylline (n = 17–32). *P < 0.05. (E) Quantification of the relative surface expression of HA-tagged rat TREK-1b in the presence or absence of mouse Popdc2 (n = 27 and 19, respectively). ni, noninjected control oocytes (n = 12). *P < 0.05. (F and G) Immunostaining of Popdc1 (red) or TREK-1 (green) transfected individually (F) or both together (G) into Cos-7 cells. Nuclei were counterstained with DAPI. Scale bars: 10 μm. (H) Example of a GST pulldown experiment using the C terminus of Popdc1 fused to GST and Flag-tagged human TREK-1. GST-E12 and GST proteins were used as controls.
The interaction of Popdc proteins with TREK-1 is modulated by cAMP. The ability of Popdc1 to directly interact with TREK-1 was used to analyze whether cAMP binding might affect complex formation of Popdc1 and TREK-1. For this experiment, we used a bimolecular fluorescence resonance energy transfer (FRET) sensor (Figure 6A). Upon coexpression of cyan fluorescent protein–tagged Popdc1 (Popdc1-CFP) and yellow fluorescent protein–tagged TREK-1 (YFP–TREK-1) in 293A cells, a robust FRET signal confirmed that both proteins interacted directly (Figure 6B). Addition of isoproterenol or forskolin to stimulate cAMP production in these cells resulted in a rapid decline of the YFP/CFP ratio, with the characteristic kinetic of an adenylyl cyclase–dependent process (Figure 6, B, D, and F). Notably, isoproterenol failed to change the FRET signal when the cAMP binding–deficient Popdc1D200A mutant protein was tested (Figure 6, C and F). The addition of sodium nitroprusside to stimulate cGMP production revealed that physiological concentrations of cGMP did not affect the FRET signal (Figure 6, E and F). The cAMP-mediated modulation of the Popdc1–TREK-1 interaction appeared to be a direct allosteric effect of binding, since it was not altered by the PKA inhibitor H89 (Figure 6F). Quantification of the cAMP concentration in cells after isoproterenol treatment using the Epac1-camps sensor for cAMP level calibration (27) established a cAMP/Popdc1 EC50 of approximately 330 nM (Figure 6, G and H), which is in agreement with the affinity data obtained by the radioligand binding assay (Figure 4H).
The interaction of Popdc1 and TREK-1 is modulated by cAMP. (A) Schematic depiction of the bimolecular FRET sensor to study the interaction of Popdc1 and TREK-1. (B–E) FRET measurements of 293A cells transfected with YFP–TREK-1 together with Popdc1-CFP (B, D, and E) or Popdc1D200A-CFP (C). Cells were stimulated with isoproterenol (B and C), forskolin (D), or sodium nitroprusside (SNP) followed by the addition of forskolin (E). Values are normalized YFP/CFP ratios. (F) Summary of the observed relative changes of FRET signals (mean ± SEM). ISO, isoproterenol; Mut ISO, Popdc1D200A-CFP treated with isoproterenol; H89 ISO, addition of PKA inhibitor H89 and isoproterenol. (G and H) Concentration-dependent response curve for isoproterenol-induced FRET signals using Epac1-camps (G) or Popdc1-CFP/YFP–TREK-1 (H).
In this report, we demonstrated that loss of function mutations in Popdc1 and Popdc2 genes in mice are associated with stress-induced SND, resulting in chronotropic incompetence and long sinus pauses. The Popdc genes displayed overlapping myocardial expression patterns and similar biochemical properties, and the cardiac phenotypes of the null mutants were nearly identical. Our data suggest that Popdc proteins represent a novel class of cAMP binding proteins that interact with TREK-1 channels and may be involved in channel trafficking.
Age-dependent decline in cardiac pacemaking in Popdc null mutants. Both mouse mutants developed SND at advanced age. Assuming that Popdc genes act in the same pathway, loss of a single gene might not have a significant impact on function in the young, since both Popdc genes might be able to substitute for each other. Obviously, the compensation became less efficient when the null mutants aged, possibly due to an age-dependent decline of Popdc expression. Alternatively, the concentration of essential interacting proteins might become limiting. Preliminary electrophysiological analysis of double homozygous Popdc1/Popdc2 mutant mice lends support to the hypothesis of functional redundancy. Double null animals displayed decreased tolerance to stress and frequently underwent sudden cardiac death under stress conditions. This is consistent with an augmented heart phenotype when both Popdc genes are absent.
Cardiac pacemaking depends on spontaneous sarcoplasmic reticulum Ca2+ cycling, which is driven by cAMP-mediated, PKA-dependent phosphorylation and interacts with a network of plasma membrane localized ion channels (7). At present, it is unclear how Popdc proteins might fit into this intricate network, but it is likely that an abundantly expressed and membrane localized cAMP-binding protein could have an important role in cAMP signaling and/or compartmentalization in cardiac myocytes. It is tempting to speculate that cAMP binding to Popdc proteins modulates the function of pacemaker currents. Therefore, it will be important to study the impact of age on cAMP levels in sinus node cells and the downstream signaling cascades of cAMP in response to β-adrenergic receptor stimulation (28, 29). Of note, older sinus node myocytes show a blunted chronotropic response after phosphodiesterase inhibition (30). Moreover, an age-associated decline in Ca2+ cycling occurs in ventricular myocytes and in sinus node cells (31). Thus, in the Popdc null mutants, the loss of a potential mediator of cAMP signaling may be further exacerbated by an age-dependent decline in cAMP signaling. This may explain why only a stress-induced phenotype was observed.
SND in humans is a disease of unknown etiology. It is often associated with a loss of pacemaker tissue, increased fibrosis, and a growing distance between the sinus node and working myocardium (32). While the disease is heterogeneous, there is a strong association with age. Moreover, in a substantial number of cases, a genetic basis seems likely, and point mutations in genes encoding ion channels and proteins involved in channel trafficking have been associated with SND (33–36). Our observation that both Popdc null mutants had SND suggests that these genes may be candidate genes for this disease and that mutations might be found in familial cases. Moreover, the mouse mutants can be considered suitable models for studying the etiology of SND and possible therapies.
Interaction of Popdc proteins with TREK-1. Increasing evidence points to the fact that ion channels act in the context of macromolecular signaling complexes, consisting of pore-forming subunits in association with auxiliary subunits, regulatory enzymes, and proteins that are involved in membrane targeting and complex formation (37). Cardiac arrhythmias are associated with mutations in genes encoding ion channels as well as proteins involved in targeting channels to the membrane or acting as β subunits (38). In Xenopus oocytes, we found a strong correlation between the ability of Popdc protein to enhance TREK-1 current and the recruitment of TREK-1 channels to the plasma membrane. Thus, Popdc proteins are potentially acting on TREK-1 channel trafficking.
In neuronal cells, TREK-1 has previously been shown to play an essential role as a background K+ channel, setting the resting membrane potential and modulating action potentials (39). Although TREK-1 is expressed in the heart, together with other related 2-pore domain channels, its role — particularly in pacemaking — has not yet been established (40). Interestingly, ORK1, a TREK-1 ortholog in Drosophila, performs essential pacemaking functions in the fly heart (41). It is tempting to hypothesize that direct binding of cAMP to Popdc proteins in a complex with TREK-1 at the plasma membrane provides a mechanism by which adrenergic stimulation regulates TREK-1 gating. This would be a novel mode of modulation that works in addition to the well-established inhibition of TREK-1 through direct phosphorylation by PKA (23, 42). In this regard, our bimolecular FRET data supported a direct modulatory role of cAMP, which affected the interaction of TREK-1 and Popdc proteins. In Xenopus oocytes, Popdc1 affected membrane trafficking of TREK-1. Experiments in cardiac myocytes will be needed to further study how Popdc proteins affect TREK-1 activity, in particular after adrenergic stimulation. It will also be important to assess whether cardiac pacemaker function is altered in the TREK-1 null mutant (43).
TREK-1 induces filopodia formation through interaction with the actin cytoskeleton (26), and after cotransfection, Popdc1 was also present in these membrane protrusions, which suggests that TREK-1 and Popdc1 might be part of the same macromolecular complex. TREK-1 is known to interact with AKAP150, a PKA anchor protein, as well as Mtap2, a microtubule-associated protein (44–46). Mtap2 enhances TREK-1 current by recruiting channel proteins to the plasma membrane. On the other hand, AKAP150 interaction with TREK-1 enhances gating, but also modifies the channel properties. It has also been shown that the coexpression of both interacting proteins provides additive effects on TREK-1 current (44–46). Thus, it will be interesting to study the modulation of TREK-1 current in the presence of Popdc proteins and these other TREK-1 interaction partners.
It is likely that, in addition to TREK-1, other interacting proteins are contributing to the bradycardia phenotype. This assumption is based on the abundance of Popdc proteins. In particular, Popdc2 was highly expressed in cardiac myocytes, and therefore probably will have other interaction partners in addition to TREK-1. These proteins could contribute to the stress-induced bradycardia phenotype. We are currently screening for such Popdc-interacting proteins using several independent approaches. Apart from ion channels and pumps, it is possible that Popdc also interacts with proteins involved in channel oligomerization or membrane trafficking. VAMP2/3 and GEFT are 2 proteins that have been shown to interact with Popdc1 (47, 48). VAMP2/3 has been shown to be involved in membrane vesicle fusion and could be involved in ion channel trafficking. GEFT, on the other hand, is a regulator of RhoA, and this interaction may be responsible for the cell shape changes that were observed in the sinus node of Popdc null mutants. However, it is not presently known whether Popdc2 is also interacting with VAMP2/3 and GEFT.
Popdc proteins represent a class of cAMP-binding proteins that we believe to be novel. Despite the importance of cAMP as a second messenger molecule involved in numerous physiological regulatory modules, only a limited number of effector proteins are known to date (49). The most important effector is PKA, which is responsible for many of the molecular changes that occur in response to rising levels of cAMP. In addition to PKA, Epac proteins couple intracellular cAMP to the activation of Rap1, a Ras family GTPase that regulates cell adhesion, proliferation, and differentiation (50). Thus, structural changes in response to an elevation in cAMP levels are probably regulated to a large extent by EPAC proteins. Several ion channels also directly bind cyclic nucleotides, which modulates the activation characteristics or gating properties of these channels; therefore, cAMP regulates membrane potential and excitability of cells. Although HCN4 plays an important role in cardiac pacemaker function (51, 52), despite its ability to directly bind cAMP, its role in stress adaptation of the cardiac pacemaker remains a matter of debate (51, 53–55). Therefore, our present identification of Popdc proteins as a class of membrane-localized cAMP binding proteins in sinus node cells and our finding that genetic loss resulted in stress-induced bradycardia suggest that Popdc proteins are part of the molecular network involved in cardiac pacemaker regulation in response to adrenergic stimulation. We believe the Popeye domain represents a novel class of cAMP-binding domain, and its PBC is highly divergent from that of other cAMP effector proteins (56, 57). This sequence divergence provides the opportunity to develop novel pharmacological agents to specifically target Popdc function and to study its role in health and disease.
Further information can be found in Supplemental Methods.
Mice. The Popdc2 null mutant was engineered by replacing the coding sequence of the first exon with the LacZ reporter gene (Supplemental Figure 1). The Popdc1 null mutant mouse was described previously (18).
ECG. To assess cardiac size, morphology, and function, 2-dimensional echocardiography and Doppler measurements were performed using 13.5-MHz 2 D and M Mode and 12-MHz Doppler transducers (HP Sonos) and a small animal ultrasound platform (VEVO770) equipped with a 50-MHz transducer following published protocols (58, 59).
ECG and telemetry. ECGs in freely roaming animals were recorded in littermate pairs at 3, 5.5, and 8 month of age. The telemetric ECG was analyzed during normal activity and during defined stress tests, i.e., swimming, air jets, or isoproterenol (60, 61). Surface ECG data at baseline and after isoproterenol stimulation (2 mg/kg body weight) were obtained in anesthetized animals. For invasive electrophysiological testing, an octapolar 2-French catheter was used. Incremental atrial pacing was performed until the first impulse was blocked in the AV node (Wenckebach point).
Electrophysiological study in the isolated heart. Intrinsic heart rate and pauses were recorded at baseline and during perfusion with 1.6 μM orciprenaline in Langendorff-perfused hearts (60, 61).
Enzyme histochemistry. β-Galactosidase and acetylcholinesterase stainings were performed as described previously (20, 62).
Whole-mount in situ hybridization. The inflow tract of an adult heart was subjected to whole-mount in situ hybridization using a Popdc2 cRNA probe as described elsewhere (63).
PCR analysis. qPCR was performed using SYBR Green. See Supplemental Methods for details and primer sequences.
Mutagenesis. Popdc1D200A, Popdc1P202A, Popdc1E203A, Popdc1V217F, and Popdc2D184A were generated by site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). See Supplemental Methods for details and primer sequences.
cAMP affinity precipitation. Lysates of transfected cells or dissected tissues were incubated with cAMP-agarose. Binding was competed with varying concentrations of free cAMP. Bound protein was detected by Western blot analysis.
Surface expression analysis. Surface expression of HA-tagged TREK-1 in the presence or absence of Popdc2 was quantitated by an immunoluminometric assay as described previously (64).
GST pulldown. Cell lysate of Cos-7 cells transiently transfected with TREK-1–Flag was added to GST-Bves, GST-E12, or GST protein bound to glutathione-sepharose 4B beads. Bound protein was detected by Western blot analysis.
Western blot analysis. Protein samples were run on SDS-PAGE and immunoblotted with the following antibodies: α-chick Popdc1 (Pop1 3F11; ref. 65), α-mouse Popdc1 (BVES C-20; Santa Cruz), α-Myc (9E10; Abcam), α-FLAG (M2; Sigma-Aldrich).
Measurement of TREK-1 current. Human TREK-1c cRNA together with mouse Popdc cRNAs were injected into Xenopus laevis oocytes, and 2-electrode voltage-clamp measurements were performed 24–72 hours after injection (25).
Electrophysiology of sinus node myocytes. Single myocytes from the sinus node were isolated and prepared for electrophysiological recordings as described previously (66, 67). If was recorded with the whole-cell patch-clamp recording in the presence or absence of 8-Br-cAMP.
Modeling of the Popeye domain. Modeling of the Popeye domain of human POPDC1 was based on the structure of the N-terminal domain of a transcriptional regulator from Streptomyces coelicolor (PDB entry 2PQQ) and the cAMP-binding domain of cAMP-dependent protein kinase (PKA; PDB entry 1CX4).
FRET assay. 293A cells were transiently transfected with Popdc1-CFP and YFP–TREK-1 constructs, and FRET measurements were performed 24 hours later using a Zeiss Axiovert 200 inverted microscope.
Radioligand binding assay. Purified GST fusion protein of the C terminus of Popdc1 was incubated with [3H]-cAMP and increasing concentrations of unlabeled cAMP or cGMP, and the bound radioactivity was measured.
Statistics. Paired and unpaired 2-tailed t tests, univariate ANOVA, and ANOVA analyses for multiple comparisons and repetitive measurements were used for comparison of continuous parameters at different cycle lengths in WT, Popdc1–/–, and Popdc2–/– mutant mice at baseline and with drugs. Fisher exact test was used to compare hearts with occurrence of sinus pauses. Unless otherwise indicated, values are mean ± SEM. Statistical significance was accepted at a P value less than 0.05.
Study approval. Mouse handling and experimentation were performed following institutional guidelines and were approved by the University of Münster institutional animal care and use committee (protocol nos. G61/99, G83/2004).
This work was supported by Deutsche Forschungsgemeinschaft (DFG) grants BR1218/9-4 (to T. Brand) and DE-1482/3-2 (to N. Decher); by Graduate College grants 1048 ‘Organogenesis’ (to T. Brand), SFB 656 A8 (to L. Fabritz and P. Kirchhof), Ki 731 (to P. Kirchhof), and FA 413/3-1 (to L. Fabritz); by the Interdisciplinary Center for Clinical Research (IZKF) Münster Core Unit CarTel (to P. Kirchhof) and grant Kih1/020/07 (to L. Fabritz); and by Fondation Leducq (to P. Kirchhof). We thank Christian Dees, Reinhild Fischer, Elisabeth Meyer-Natus, Nina Kreienkamp, Daniela Volkery, Marco Abesser, Ursula Herbort-Brand, and Marcel Tekook for excellent technical assistance and Lisa Fortmüller for help with the in vivo pathophysiology.
Address correspondence to: Thomas Brand, Harefield Heart Science Centre, National Heart and Lung Institute, Imperial College London, Harefield, UB9 6JH, United Kingdom. Phone: 44.0.1895.453.826; Fax: 44.0.1895.828.900; E-mail: t.brand@imperial.ac.uk.
Conflict of interest: The authors have declared that no conflict of interest exists.
Reference information: J Clin Invest. 2012;122(3):1119–1130. doi:10.1172/JCI59410.
Alexander Froese and Stephanie S. Breher’s present address is: Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
Roland F.R. Schindler, Jan Schlueter, and Thomas Brand’s present address is: Heart Science Centre, Imperial College London, Harefield, United Kingdom.
Viacheslav Nikolaev’s present address is: Department of Cardiology and Pneumology, University of Göttingen, Göttingen, Germany.
Juliane Khutz’s present address is: Institute of Human Genetics, University of Würzburg, Würzburg, Germany.
Patrick Meister’s present address is: Developmental Biochemistry, University of Würzburg, Würzburg, Germany.
Sonja Kreissl’s present address is: Comprehensive Heart Failure Center (CHFC), University Hospital Würzburg, Würzburg, Germany.
Angela Torlopp’s present address is: Cell and Developmental Biology, University College London, London, United Kingdom.
Larissa Fabritz and Paulus Kirchhof’s present address is: Centre for Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.
See the related article at Popeye proteins: muscle for the aging sinus node.